Press Releases

Date Title and Summary Additional Formats
Toggle Summary Aravive Added to the Russell 2000® and Russell 3000® Indexes
HOUSTON , June 30, 2020 (GLOBE NEWSWIRE) -- Aravive , Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis, today announced that the Company has been added to the Russell
View HTML
Toggle Summary Aravive and AstraZeneca Announce Initiation of Randomized Phase 1/2 Study of AVB-500 in Combination with Durvalumab in Patients with Platinum-Resistant Recurrent Epithelial Ovarian Cancer
Investigator-sponsored study being conducted in clinical collaboration with Aravive and AstraZeneca HOUSTON and WILMINGTON, Del. , Nov. 12, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV) and AstraZeneca (NYSE: AZN) today announced that an investigator-sponsored Phase 1/2 clinical trial of
View HTML
Toggle Summary Aravive and WuXi Biologics Form Strategic Collaboration to Develop Novel High-Affinity Bispecific Antibodies Targeting Cancer and Fibrosis Using the WuXiBody™ Platform
HOUSTON and SHANGHAI , April 30, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, and WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced a strategic collaboration
View HTML
Toggle Summary Aravive Announces AVB-500 Improves Anti-Tumor Effects when Combined with Anti-Angiogenic Bevacizumab or PARP Inhibitor Olaparib in Preclinical Models of Uterine Cancer
Inhibition of GAS6/AXL signaling induces ‘BRCAness’ in preclinical model of ovarian cancer, increasing response to platinum chemotherapy and PARP inhibitor Multiple Abstracts Published on Website of the Society for Gynecologic Oncology 2020 Annual Meeting Recorded Webcast and Posters to be
View HTML
Toggle Summary Aravive Announces Board Composition and Executive Management Transitions
Healthcare Entrepreneur Fred Eshelman , Pharm.D., Appointed Board Chairman Aravive’s Chief Scientific Officer, Gail McIntyre , Ph.D., Appointed CEO Aravive to Host Conference Call Today at 9:00 AM  ET HOUSTON , April 09, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc.
View HTML
Toggle Summary Aravive Announces Dose Escalation of AVB-500 in Recurrent Platinum Resistant Ovarian Cancer Phase 1b Trial
Dose escalation of AVB-500 to 20mg/kg dose follows positive recommendation by independent Data Monitoring Committee review Plan to initiate Phase 2/3 study in Platinum Resistant Ovarian Cancer by year end 2020 HOUSTON , Feb. 18, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc.
View HTML
Toggle Summary Aravive Announces Executive Management Transition Plan
CEO Jay Shepard to step down from his current role after a successor is appointed HOUSTON , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, including
View HTML
Toggle Summary Aravive Announces Independent Data Monitoring Committee Recommends Continuation of Phase Ib Study of AVB-500 In Recurrent Platinum Resistant Ovarian Cancer After Review of First Two Cohorts of Patients
AVB-500 demonstrates favorable safety profile and full suppression of circulating GAS6 in cancer patients HOUSTON , July 08, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. ( Aravive ) (NASDAQ:ARAV), a clinical-stage biopharmaceutical company, announced that the independent Data Monitoring Committtee (DMC)
View HTML
Toggle Summary Aravive Announces Initiation of Investigator-Sponsored Phase 1/2 Study of AVB-500 in Combination with Avelumab in Patients with Advanced Urothelial Carcinoma (COAXIN)
HOUSTON , March 24, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, announced that the first patient has been dosed in an investigator-sponsored Phase 1/2 clinical trial of the company’s GAS6/AXL inhibitor AVB-500 in combination with PD-L1
View HTML
Toggle Summary Aravive Announces Management Changes
Rekha Hemrajani Appointed President, Chief Executive Officer and Director to Execute Corporate Strategy as Company Advances Clinical Pipeline Jay Shepard to Assume Role of Chairman of the Board of Directors HOUSTON , Jan. 09, 2020 (GLOBE NEWSWIRE) -- Aravive , Inc. (Nasdaq: ARAV), a clinical-stage
View HTML